Michael G. Kauffman
2019
In 2019, Michael G. Kauffman earned a total compensation of $3.2M as Chief Executive Officer at Karyopharm Therapeutics, a 42% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $363,693 |
|---|---|
| Option Awards | $1,486,339 |
| Salary | $566,500 |
| Stock Awards | $803,112 |
| Other | $11,860 |
| Total | $3,231,504 |
Kauffman received $1.5M in option awards, accounting for 46% of the total pay in 2019.
Kauffman also received $363.7K in non-equity incentive plan, $566.5K in salary, $803.1K in stock awards and $11.9K in other compensation.
Rankings
In 2019, Michael G. Kauffman's compensation ranked 3,776th out of 13,971 executives tracked by ExecPay. In other words, Kauffman earned more than 73.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,776 out of 13,971 | 73rd |
Division Manufacturing | 1,366 out of 5,701 | 76th |
Major group Chemicals And Allied Products | 477 out of 2,200 | 78th |
Industry group Drugs | 401 out of 1,886 | 79th |
Industry Pharmaceutical Preparations | 302 out of 1,398 | 78th |
Source: SEC filing on April 9, 2020.
Kauffman's colleagues
We found three more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2019.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019